Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133407 | 0.88 | HTR1A (0.43) | HTR1AHTR7HTR1DGRIN2BDRD2 | |
| SCHEMBL4130376 | 0.88 | HTR1A (0.43) | HTR1AHTR7HTR1DGRIN2BDRD2 | |
| SCHEMBL4148545 | 0.87 | HTR1A (0.44) | HTR1AHTR7HTR1DHRH3GRIN2B | |
| SCHEMBL4135988 | 0.85 | HTR1A (0.49) | HTR1AHTR7HTR1DHRH3GRIN2B | |
| SCHEMBL4136479 | 0.85 | NAAA (0.51) | HTR1AHTR7CYP11B2CYP3A4CYP11B1 | |
| SCHEMBL4132535 | 0.84 | OPRM1 (0.44) | HTR1AHTR7HTR1DHRH3GRIN2B | |
| SCHEMBL4136629 | 0.84 | OPRM1 (0.44) | HTR1AHTR7HTR1DHRH3GRIN2B | |
| SCHEMBL4141143 | 0.84 | OPRM1 (0.44) | HTR1AHTR7HTR1DHRH3GRIN2B | |
| SCHEMBL4141125 | 0.84 | HTR1A (0.47) | HTR1AHTR7HTR1DHRH3GRIN2B | |
| SCHEMBL4132412 | 0.83 | HTR1A (0.47) | HTR1AHTR7HTR1DGRIN2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HTR1A 19/4885HTR7 7/4885HTR1D 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.